2026-08-05T11:42:06Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/104342025-04-07T13:30:22Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16971

00925njm 22002777a 4500 dc Jarrin Vera, Inmaculada author Pantazis, Nikos author Dalmau, Judith author Phillips, Andrew N author Olson, Ashley author Mussini, Cristina author Boufassa, Faroudy author Costagliola, Dominique author Porter, Kholoud author Blanco, Juliá author Amo, Julia del author Martinez-Picado, Javier author CASCADE Collaboration in EuroCoord author 2015-11 Objective: This article compares trends in CD4þ T-cell recovery and proportions achieving optimal restoration ( 500 cells/ml) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. Methods: We included HIV-1 seroconverters achieving viral suppression within 6 months of cART. Rapid progressors were individuals experiencing at least one CD4þ less than 200 cells/ml within 12 months of seroconverters before cART. We used piecewise linear mixed models and logistic regression for optimal restoration. Results: Of 4024 individuals, 294 (7.3%) were classified as rapid progressors. At the same CD4þ T-cell count at cART start (baseline), rapid progressors experienced faster CD4þ T-cell increases than nonrapid progressors in first month [difference (95% confidence interval) in mean increase/month (square root scale): 1.82 (1.61; 2.04)], which reversed to slightly slower increases in months 1–18 [0.05 (0.06; 0.03)] and no significant differences in 18–60 months [0.003 (0.01; 0.01)]. Percentage achieving optimal restoration was significantly lower for rapid progressors than nonrapid progressors at months 12 (29.2 vs. 62.5%) and 36 (47.1 vs. 72.4%) but not at month 60 (70.4 vs. 71.8%). These differences disappeared after adjusting for baseline CD4þ T-cell count: odds ratio (95% confidence interval) 0.86 (0.61; 1.20), 0.90 (0.38; 2.17) and 1.56 (0.55; 4.46) at months 12, 36 and 60, respectively. Conclusion: Among people on suppressive antiretroviral therapy, rapid progressors experience faster initial increases of CD4þ T-cell counts than nonrapid progressors, but are less likely to achieve optimal restoration during the first 36 months after cART, mainly because of lower CD4þ T-cell counts at cART initiation. AIDS. 2015 Nov;29(17):2323-33. 10.1097/QAD.0000000000000805 1473-5571 AIDS (London, England) 26544704 http://hdl.handle.net/20.500.12105/10434 CD4 responses HIV-viral suppression Rapid progression Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?